ATE357227T1 - Verwendung von aminosäurehältigen antikonvulsiva zur behandlung von schmerz - Google Patents

Verwendung von aminosäurehältigen antikonvulsiva zur behandlung von schmerz

Info

Publication number
ATE357227T1
ATE357227T1 AT01966230T AT01966230T ATE357227T1 AT E357227 T1 ATE357227 T1 AT E357227T1 AT 01966230 T AT01966230 T AT 01966230T AT 01966230 T AT01966230 T AT 01966230T AT E357227 T1 ATE357227 T1 AT E357227T1
Authority
AT
Austria
Prior art keywords
lower alkyl
aryl
heterocyclic
unsubstituted
substituted
Prior art date
Application number
AT01966230T
Other languages
English (en)
Inventor
Robert H Harris
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Application granted granted Critical
Publication of ATE357227T1 publication Critical patent/ATE357227T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT01966230T 2000-08-25 2001-08-24 Verwendung von aminosäurehältigen antikonvulsiva zur behandlung von schmerz ATE357227T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22823000P 2000-08-25 2000-08-25

Publications (1)

Publication Number Publication Date
ATE357227T1 true ATE357227T1 (de) 2007-04-15

Family

ID=22856332

Family Applications (4)

Application Number Title Priority Date Filing Date
AT04021728T ATE375793T1 (de) 2000-08-25 2001-08-24 Verwendungen von antikonvulsiven aminosäure zur behandlung bipolarer erkrankungen
AT06012400T ATE476971T1 (de) 2000-08-25 2001-08-24 Aminosäure enthaltende antikonvulsiva zur behandlung von zwangsstörungen
AT04021727T ATE375792T1 (de) 2000-08-25 2001-08-24 Verwendung von antikonvulsiven aminosäure zur behandlung von migräne
AT01966230T ATE357227T1 (de) 2000-08-25 2001-08-24 Verwendung von aminosäurehältigen antikonvulsiva zur behandlung von schmerz

Family Applications Before (3)

Application Number Title Priority Date Filing Date
AT04021728T ATE375793T1 (de) 2000-08-25 2001-08-24 Verwendungen von antikonvulsiven aminosäure zur behandlung bipolarer erkrankungen
AT06012400T ATE476971T1 (de) 2000-08-25 2001-08-24 Aminosäure enthaltende antikonvulsiva zur behandlung von zwangsstörungen
AT04021727T ATE375792T1 (de) 2000-08-25 2001-08-24 Verwendung von antikonvulsiven aminosäure zur behandlung von migräne

Country Status (13)

Country Link
US (6) US6884910B2 (de)
EP (5) EP1695703B1 (de)
JP (2) JP4307068B2 (de)
AT (4) ATE375793T1 (de)
AU (6) AU2001286763C1 (de)
CA (2) CA2419285C (de)
CY (5) CY1107668T1 (de)
DE (4) DE60131032T2 (de)
DK (4) DK1486206T3 (de)
ES (5) ES2348646T3 (de)
LU (1) LU91512I2 (de)
PT (4) PT1486206E (de)
WO (1) WO2002015922A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1486206E (pt) 2000-08-25 2008-01-25 Res Corp Technologies Inc ¿utilizações para aminoácidos anticonvulsivantes para o tratamento de perturbações bipolares¿
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
PT1243263E (pt) 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
US20050233472A1 (en) * 2003-09-19 2005-10-20 Kao H P Spotting high density plate using a banded format
KR20060111524A (ko) * 2003-12-02 2006-10-27 쉬바르츠파르마에이지 펩타이드 화합물들의 중추 신경병증성 통증 치료를 위한신규한 용도
EP1537862A1 (de) * 2003-12-02 2005-06-08 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von zentralen neuropathische-Schmerzen
EP1579858A1 (de) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie
US8008351B2 (en) * 2004-04-16 2011-08-30 Ucb Pharma Gmbh Methods for prophylaxis or treatment of conditions associated with cortical spreading depression
EP1604654A1 (de) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Dyskynesien
EP1604655A1 (de) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
EP1629839A1 (de) * 2004-08-27 2006-03-01 Schwarz Pharma Ag Verwendung von Peptidverbindungen zur Behandlung von Knochenkrebsschmerz sowie von Chemotherapie- oder Nukleosid-induziertem Schmerz
EP1781276B1 (de) * 2004-08-27 2010-06-23 UCB Pharma GmbH Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (de) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
EP1920780A1 (de) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptidverbindungen zur Behandlung von Krankheiten mit erhöhter Erregbarkeit
EA027836B1 (ru) * 2006-06-15 2017-09-29 ЮСиБи ФАРМА ГМБХ Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
US7489198B1 (en) 2007-04-26 2009-02-10 Lockheed Martin Corporation Linear regulating switch
WO2011101863A2 (en) 2010-02-19 2011-08-25 Cadila Healthcare Limited Extended release pharmaceutical compositions of lacosamide
RU2721401C2 (ru) * 2014-06-23 2020-05-19 Нортвестерн Юниверсити Способы лечения или облегчения мигрени
KR20180064535A (ko) 2015-11-03 2018-06-14 킴벌리-클라크 월드와이드, 인크. 고 벌크 및 저 린트를 갖는 페이퍼 티슈
US11255051B2 (en) 2017-11-29 2022-02-22 Kimberly-Clark Worldwide, Inc. Fibrous sheet with improved properties
WO2020023027A1 (en) 2018-07-25 2020-01-30 Kimberly-Clark Worldwide, Inc. Process for making three-dimensional foam-laid nonwovens

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795788A (nl) * 1972-02-22 1973-08-22 Akzo Nv Werkwijze ter bereiding van peptiden en peptide-derivaten en de toepassing hiervan
US4533657A (en) * 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
US4510082A (en) * 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
FR2546517B1 (fr) * 1983-05-24 1987-04-24 Panmedica Nouveaux dipeptides du -l-5-hydroxy-tryptophane, procedes pour leur preparation et medicaments les contenant
JPH0680079B2 (ja) * 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5654301A (en) * 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5331089A (en) * 1988-03-25 1994-07-19 Merck Sharpe & Dohme, Ltd. Peptides useful as tachykinin agonists
US5178729A (en) * 1991-01-15 1993-01-12 James River Corporation Of Virginia High purity stratified tissue and method of making same
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
AU5890394A (en) 1993-02-03 1994-08-29 Steven Andrew Jennings Blends of glycine derivatives and sugars
ATE198551T1 (de) * 1993-07-15 2001-01-15 Hoffmann La Roche Pharmazeutische kombination, die einen hemmer des renin-angiotensin-systems und einen endothelin- antagonisten enthält
GB9318637D0 (en) * 1993-09-08 1993-10-27 Ferring Res Ltd Enzyme inhibitors
US5508266A (en) * 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
US6348571B1 (en) * 1994-09-12 2002-02-19 Northwestern University Corticotropin release inhibiting factor and methods of using same
JP3787605B2 (ja) * 1994-10-05 2006-06-21 ダーウィン・ディスカバリー・リミテッド ペプチジル化合物および金属プロテアーゼのインヒビターとしてのその治療的使用
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US5780589A (en) * 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
US6514937B1 (en) * 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6197746B1 (en) * 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
DE69833858T2 (de) 1997-07-08 2007-02-22 Ono Pharmaceutical Co. Ltd. Aminosäurederivate
KR100522012B1 (ko) 1997-07-08 2005-10-18 오노 야꾸힝 고교 가부시키가이샤 아미노산 유도체
DE69808475T2 (de) 1997-07-15 2003-01-30 Res Corp Technologies Inc Aminosäurederivate zur behandlung von schlaganfall
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
EP2338482A3 (de) * 1998-04-14 2011-12-21 The General Hospital Corporation Verfahren zur Behandlung neuropsychischer Erkrankungen
DE69930624T2 (de) 1998-06-10 2006-09-14 Meiji Seika Kaisha Ltd. Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US6399574B1 (en) * 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
PT1486206E (pt) 2000-08-25 2008-01-25 Res Corp Technologies Inc ¿utilizações para aminoácidos anticonvulsivantes para o tratamento de perturbações bipolares¿
US6228825B1 (en) 2000-10-13 2001-05-08 Colgate Palmolive Company Automatic dishwashing cleaning system
DE60120104T2 (de) * 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz

Also Published As

Publication number Publication date
WO2002015922A3 (en) 2003-09-25
EP1486205A1 (de) 2004-12-15
AU2009202362B2 (en) 2011-01-27
JP5190334B2 (ja) 2013-04-24
US6884910B2 (en) 2005-04-26
CY2009002I2 (el) 2009-11-04
AU2001286763B2 (en) 2005-11-24
ES2435000T3 (es) 2013-12-18
ES2294414T3 (es) 2008-04-01
EP1695703A3 (de) 2006-12-13
CY1107852T1 (el) 2013-06-19
EP1486206A1 (de) 2004-12-15
DE60131032T2 (de) 2008-08-14
EP2210598B1 (de) 2013-09-18
ES2294415T3 (es) 2008-04-01
PT1695703E (pt) 2010-11-16
AU2007202336B9 (en) 2009-10-29
US7186859B2 (en) 2007-03-06
AU2011202293B2 (en) 2013-01-10
DE60131033D1 (de) 2007-11-29
DE60127459D1 (de) 2007-05-03
AU2001286763C1 (en) 2006-03-02
AU2007202336B2 (en) 2009-09-24
CA2740815C (en) 2014-03-18
CY2009002I1 (el) 2009-11-04
DK1695703T3 (da) 2010-10-25
ATE476971T1 (de) 2010-08-15
PT1486206E (pt) 2008-01-25
AU2011202293A1 (en) 2011-06-09
CA2740815A1 (en) 2002-02-28
ES2348646T3 (es) 2010-12-10
CY1107853T1 (el) 2013-06-19
US20100273716A1 (en) 2010-10-28
AU2009202363A1 (en) 2009-07-02
JP2004506692A (ja) 2004-03-04
CY1107668T1 (el) 2010-07-28
US20070142297A1 (en) 2007-06-21
DE60127459T2 (de) 2007-07-12
US20130316953A1 (en) 2013-11-28
EP1695703B1 (de) 2010-08-11
EP1695703A2 (de) 2006-08-30
AU2007202336A1 (en) 2007-06-14
WO2002015922A2 (en) 2002-02-28
EP2210598A3 (de) 2011-07-20
CY1112349T1 (el) 2015-12-09
EP1486205B1 (de) 2007-10-17
DE60131033T2 (de) 2008-07-17
CA2419285C (en) 2011-08-02
US7148378B2 (en) 2006-12-12
CA2419285A1 (en) 2002-02-28
US7772427B2 (en) 2010-08-10
US20040087508A1 (en) 2004-05-06
LU91512I2 (fr) 2009-03-16
AU8676301A (en) 2002-03-04
DE60142806D1 (de) 2010-09-23
JP2009108090A (ja) 2009-05-21
EP1365787B1 (de) 2007-03-21
EP1365787A2 (de) 2003-12-03
AU2009202363B2 (en) 2011-02-17
JP4307068B2 (ja) 2009-08-05
DE60131032D1 (de) 2007-11-29
US8519183B2 (en) 2013-08-27
EP2210598A2 (de) 2010-07-28
US20020086828A1 (en) 2002-07-04
DK1486206T3 (da) 2008-02-11
PT1365787E (pt) 2007-06-29
DK1365787T3 (da) 2007-07-23
ES2281439T3 (es) 2007-10-01
ATE375793T1 (de) 2007-11-15
AU2009202362A1 (en) 2009-07-02
PT1486205E (pt) 2008-01-25
DK1486205T3 (da) 2008-02-18
US20040097416A1 (en) 2004-05-20
ATE375792T1 (de) 2007-11-15
EP1486206B1 (de) 2007-10-17

Similar Documents

Publication Publication Date Title
ATE357227T1 (de) Verwendung von aminosäurehältigen antikonvulsiva zur behandlung von schmerz
JP2007530493A5 (de)
JP2008501760A5 (de)
AR061743A1 (es) Compuestos peptidicos para el tratamiento de trastornos de hiperexcitabilidad y trastornos asociados con disfuncion del canal de hierro
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
JP2007532607A5 (de)
JP2008510758A5 (de)
IS8058A (is) Sýklísk súlfónamíð til að hamla gamma seytiasa
JP2008501753A5 (de)
AR061475A1 (es) Compuestos peptidicos para tratar status epilepticus refractario
BR0008365A (pt) 2-amino-6-anilino-purinas e o seu uso comomedicamento
HUP0001293A1 (hu) Heterociklusos vegyületek és ezeket tartalmazó gyógyászati készítmények béta-amiloid-peptidek gátlására
NO982731L (no) Antagonister av gonadotropinfrigivende hormon
DE60119896D1 (de) Verwendung von pramipexol zur behandlung von tabak/nikotin abhängigkeit
GEP20053423B (en) Method of Inhibiting Amyloid Protein Aggregation and Method for Imaging of Amyloid Deposits
ATE499933T1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
ATE260655T1 (de) Verwendung von stickstoffhaltigen aromatischen heterozyklusderivaten zur topischen behandlung von epithelerkrankungen
ATE204476T1 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazi e zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem
TR200103562T2 (tr) Amiloid proteini toplanmasını önleme ve amiloid birikintilerini görüntüleme yönteminde kullanım için rodanin türevleri
DE602004007304D1 (de) Verwendung von N2O zur Behandlung von postischemischen cerebralen zellulären Beschädigungen
ATE302023T1 (de) Verwendung von stickstoffoxid zur behandlung von atemwegs-verengungen
DE60122781D1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
AR050097A1 (es) Uso de compuestos peptidicos para tratar dolor en neuropatia diabetica dolorosa
DE60108775T8 (de) Methode zur behandlung von schlaganfall
TH23898A (th) วิธีการหยุดยั้งการออกฤทธิ์ของ il-6

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1365787

Country of ref document: EP